TABLE 2.
Treatment emergent adverse events of special interest
| Number of patients experiencing adverse event | |||
|---|---|---|---|
| Classification and preferred term | 120 mcg (n=19), n (%) | 180 mcg (n=14), n (%) | Total (N=33), n (%) |
| Flu-like | 13 (68.4) | 9 (64.3) | 22 (66.7) |
| Pyrexia | 8 (42.1) | 7 (50.0) | 15 (45.5) |
| Chills | 5 (26.3) | 3 (21.4) | 8 (24.2) |
| Arthralgia | 8 (42.1) | 7 (50.0) | 15 (45.5) |
| Myalgia | 5 (26.3) | 7 (50.0) | 12 (36.4) |
| Musculoskeletal | 10 (52.6) | 10 (71.4) | 20 (60.6) |
| Arthralgia | 8 (42.1) | 7 (50.0) | 15 (45.5) |
| Myalgia | 5 (26.3) | 7 (50.0) | 12 (36.4) |
| Back pain | 6 (31.6) | 3 (21.4) | 9 (27.3) |
| Constitutional | 4 (21.1) | 9 (64.3) | 13 (39.4) |
| Fatigue | 3 (15.8) | 8 (57.1) | 11 (33.3) |
| Asthenia | 1 (5.3) | 3 (21.4) | 4 (12.1) |
| Neurological | 9 (47.4) | 12 (85.7) | 21 (63.6) |
| Headache | 9 (47.4) | 12 (85.7) | 21 (63.6) |
| Dizziness | 1 (5.3) | 4 (28.6) | 5 (15.2) |
| Psychiatric | 0 | 1 (7.1) | 1 (3.0) |
| Depression | 0 | 1 (7.1) | 1 (3.0) |
| Irritability | 0 | 0 | 0 |
| Insomnia | 0 | 0 | 0 |